EUVIMEDEUVIMED entdecken
Crossref

Clinical Features of Solitary Fibrous Tumor: Insights From a Single Center Experience

Chenglong Zhou, Lijuan Zhang, Hui Wang, Yuwang Cao, Xiongbin Lan, Songbo Zhao iD

Journal of Surgical Oncology · 2026-05 · 133 (6) · 803-810

DOI: 10.1002/jso.70215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 08.03.2026. Verfasst von Chenglong Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Shengli Oilfield Central Hospital, Dongying City, Shandong, China. Hauptthemen laut MEDLINE: Solitary Fibrous Tumors, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives This study investigates the clinical characteristics, pathological features, immunohistochemical profiles, and prognostic factors of solitary fibrous tumors (SFTs) to provide insights into their management and prognosis.

Methods

A retrospective analysis was conducted on 43 cases of SFTs diagnosed at a single center. Patient demographics, tumor characteristics, immunohistochemical (IHC) markers, and outcomes were collected.

Results

Among the 43 cases, the majority of tumors were infratentorial (81%), and 60% were classified as WHO Grade 1. IHC analyses revealed high expression rates of STAT6 (62.5%), CD34 (82.5%), and Ki‐67 (100%). Ki‐67 demonstrated the strongest correlation with tumor grade and risk scores ( r = 0.62, p < 0.001; r = 0.68, p < 0.001), indicating its role as a significant prognostic marker. CD34 and STAT6 also showed moderate correlations with tumor aggressiveness. Metastatic presentations were noted in 57.5% of cases. The study highlights the heterogeneity of SFTs and the importance of IHC markers in risk stratification.

Conclusion

The findings underscore the utility of IHC markers, particularly Ki‐67, STAT6, and CD34, in assessing the aggressiveness and prognosis of SFTs. Future studies should focus on multicenter validations, integration of advanced molecular diagnostics, and long‐term follow‐up to refine risk models and therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Solitary Fibrous TumorsBiomarkers, TumorHumansFemaleRetrospective StudiesPrognosisMaleSTAT6 Transcription FactorMiddle AgedAntigens, CD34AdultKi-67 AntigenAgedFollow-Up StudiesYoung AdultImmunohistochemistry

Stichwörter der Autor:innen

CD34Demicco risk scoreKi‐67STAT6WHO gradeimmunohistochemistrysolitary fibrous tumortumor prognosis

Substanzen

Biomarkers, TumorSTAT6 Transcription FactorAntigens, CD34STAT6 protein, humanKi-67 Antigen

Autor:innen und Institutionen

  • Department of Medical Imaging, Shengli Oilfield Central Hospital, Dongying City, Shandong, China.
  • Department of Clinical Laboratory, Shengli Oilfield Central Hospital, Dongying City, Shandong, China.
  • Department of Pathology, Shengli Oilfield Central Hospital, Dongying City, Shandong, China.

ORCID-Profile: Songbo Zhao

Zitieren

APA

Zhou, C., Zhang, L., Wang, H., Cao, Y., Lan, X., & Zhao, S. (2026). Clinical Features of Solitary Fibrous Tumor: Insights From a Single Center Experience. Journal of Surgical Oncology, 133(6), 803-810. https://doi.org/10.1002/jso.70215

Vancouver

Zhou C, Zhang L, Wang H, Cao Y, Lan X, Zhao S. Clinical Features of Solitary Fibrous Tumor: Insights From a Single Center Experience. Journal of Surgical Oncology. 2026;133(6):803-810. doi:10.1002/jso.70215

BibTeX
@article{Zhou2026,
  author = {Zhou, Chenglong and Zhang, Lijuan and Wang, Hui and Cao, Yuwang and Lan, Xiongbin and Zhao, Songbo},
  title = {Clinical Features of Solitary Fibrous Tumor: Insights From a Single Center Experience},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  volume = {133},
  number = {6},
  pages = {803--810},
  doi = {10.1002/jso.70215}
}
Kostenlos starten →